# NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

> **NCT02319824** · PHASE1 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **BIOLOGICAL:** Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Palliative Radiation Therapy

## Key facts

- **NCT ID:** NCT02319824
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-06
- **Final completion:** —
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319824, "NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02319824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*